Plasma Midregional Pro-Adrenomedullin Improves Prediction of Functional Outcome in Ischemic Stroke

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Seifert Held, Thomas ^a   Pekar, Thomas ^a,b   Gattringer, Thomas ^a   Simmet, Nicole E ^a   Scharnagl, Hubert ^a   Bocksrucker, Christoph ^c   Lampl, Christian ^c,d   Storch, Maria K ^a   Stojakovic, Tatjana ^a   Fazekas, Franz ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF APPLIED SCIENCES WIENER NEUSTADT   (Austria)

^c Konventhospital Barmherzige Brueder   (Austria)

^d Headache Medical Center Seilerstaette   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROADRENOMEDULLIN;

ADULT; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREDICTION; PROGNOSIS; RANKIN SCALE; RECANALIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADRENOMEDULLIN; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN PRECURSORS; STROKE; YOUNG ADULT;

EID: 84880662211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068768     Document Type: Article

References (40)

1. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC, (2004) Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 35: 158-162.
2. Frendl A, Csiba L, (2011) Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke. Front Neurol 2: 32.
3. Whiteley W, Chong WL, Sengupta A, Sandercock P, (2009) Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40: e380-389.
4. De Marchis GM, Katan M, Weck A, Fluri F, Foerch C, et al. (2013) Copeptin adds prognostic information after ischemic stroke: Results from the CoRisk study. Neurology 80: 1278-1286.
5. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, et al. (2009) Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66: 799-808.
6. Katan M, Fluri F, Schuetz P, Morgenthaler NG, Zweifel C, et al. (2010) Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 56: 1045-1053.
7. Doehner W, von Haehling S, Suhr J, Ebner N, Schuster A, et al. (2012) Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol 60: 346-354.
8. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, et al. (2007) Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49: 1525-1532.
9. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, et al. (2010) Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12: 484-491.
10. Gumusel B, Chang JK, Hyman A, Lippton H, (1995) Adrenotensin: an ADM gene product with the opposite effects of ADM. Life Sci 57: PL87-90.
11. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, et al. (1994) Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 203: 719-726.
12. Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, et al. (1994) Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 201: 1160-1166.
13. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, et al. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192: 553-560.
14. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T, (2005) Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 25: 2480-2487.
15. Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, et al. (2001) Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 276: 12292-12300.
16. Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, et al. (1997) Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 82: 95-100.
17. Struck J, Tao C, Morgenthaler NG, Bergmann A, (2004) Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 25: 1369-1372.
18. Morgenthaler NG, Struck J, Alonso C, Bergmann A, (2005) Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51: 1823-1829.
19. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, et al. (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20: 864-870.
20. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604-607.
21. Janssen PM, Visser NA, Dorhout Mees SM, Klijn CJ, Algra A, et al. (2010) Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis 29: 137-139.
22. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC, (2013) Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology 80: 21-28.
23. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C, (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337: 1521-1526.
24. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, et al. (2007) A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 38: 2979-2984.
25. DeLong ER, DeLong DM, Clarke-Pearson DL, (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
26. Pencina MJ, D'Agostino RB Sr, Steyerberg EW, (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30: 11-21.
27. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172; discussion 207-112.
28. Faul F, Erdfelder E, Lang AG, Buchner A, (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
29. Rabinstein A, Rundek T, (2013) Prediction of outcome after ischemic stroke: The value of clinical scores. Neurology 80: 15-16.
30. Quinn TJ, Dawson J, Walters MR, Lees KR, (2009) Functional outcome measures in contemporary stroke trials. Int J Stroke 4: 200-205.
31. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, et al. (2012) Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 43: 1163-1170.
32. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, et al. (2010) The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 30: 85-92.
33. Worthmann H, Kempf T, Widera C, Tryc AB, Goldbecker A, et al. (2011) Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. Cerebrovasc Dis 32: 72-78.
34. Ferrari J, Knoflach M, Kiechl S, Willeit J, Matosevic B, et al. (2010) Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry. Stroke 41: 2001-2004.
35. Cuttitta F, Pio R, Garayoa M, Zudaire E, Julian M, et al. (2002) Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech 57: 110-119.
36. Wiesner J, Vilcinskas A, (2010) Antimicrobial peptides: the ancient arm of the human immune system. Virulence 1: 440-464.
37. Nicholls MG, Charles CJ, Lainchbury JG, Lewis LK, Rademaker MT, et al. (2003) Adrenomedullin in heart failure. Hypertens Res 26Suppl: S135-140.
38. Maki T, Ihara M, Fujita Y, Nambu T, Miyashita K, et al. (2011) Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice. Stroke 42: 1122-1128.
39. Encinas JM, Serrano J, Alonso D, Fernandez AP, Rodrigo J, (2002) Adrenomedullin over-expression in the caudate-putamen of the adult rat brain after ischaemia-reperfusion injury. Neurosci Lett 329: 197-200.
40. Serrano J, Alonso D, Encinas JM, Lopez JC, Fernandez AP, et al. (2002) Adrenomedullin expression is up-regulated by ischemia-reperfusion in the cerebral cortex of the adult rat. Neuroscience 109: 717-731.